MDRD vs CKD-EPI

Both MDRD and CKD-EPI 2021 estimate eGFR in mL/min/1.73m², from the same inputs, and both are applied race-free. The difference is accuracy: CKD-EPI is more accurate near-normal GFR and is now the preferred equation, while MDRD underestimates higher values.

Same Inputs, Same Units

Unlike the CrCl-vs-eGFR comparison, this is an eGFR-vs-eGFR question: both equations take age, sex, and serum creatinine and return mL/min/1.73m². Neither uses weight, so body size does not move either result. That makes the comparison purely about how each equation maps creatinine to filtration, not about what they measure.

Validation and Why Accuracy Differs

MDRD was derived from the Modification of Diet in Renal Disease cohort, whose participants mostly had reduced kidney function. Fitting the model on low-GFR data is why MDRD is reasonable below 60 but systematically underestimates higher, near-normal values — it should not be used to confirm normal kidney function. CKD-EPI 2021 was developed across cohorts spanning normal to low GFR, so it stays accurate across the range, including the near-normal zone where staging decisions are often made.

A Worked Comparison

For a 50-year-old man with a serum creatinine of 1.0 mg/dL, MDRD reports an eGFR of roughly 83 mL/min/1.73m², while CKD-EPI 2021 reports about 92 mL/min/1.73m². The gap is the MDRD underestimate at near-normal function; the higher CKD-EPI value is closer to measured GFR. At lower function — say an eGFR around 30 — the two equations agree much more closely, which is why MDRD remained acceptable for advanced disease.

Primary Use

Use CKD-EPI 2021 for new CKD staging and reporting. Read MDRD when a laboratory or older record still prints it, but interpret near-normal MDRD values with caution. Neither is the right tool for drug dosing — for that, use Cockcroft–Gault creatinine clearance.

The Two Equations Written Out

Seeing the formulas clarifies why they behave differently. MDRD is 175 × Scr^−1.154 × age^−0.203 × (0.742 if female) — a simple product of power terms. CKD-EPI 2021 is 142 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^−1.200 × 0.9938^age × (1.012 if female), with κ = 0.7 female / 0.9 male and α = −0.241 female / −0.302 male. The decisive structural difference is the two-part spline in CKD-EPI: it applies a gentler exponent below the Scr/κ = 1 hinge and a steeper one above it, which lets a single equation stay accurate across both near-normal and reduced function. MDRD's single power term cannot bend that way, so it sacrifices accuracy at the near-normal end.

Why MDRD Underestimates Near-Normal GFR

The bias is a direct consequence of how MDRD was derived. The Modification of Diet in Renal Disease cohort was selected for established kidney disease, so the model saw very few people with normal function during fitting. A regression is most reliable inside the range of its training data and least reliable outside it; applied to a healthy patient with near-normal GFR, MDRD extrapolates and systematically reads low. CKD-EPI was built from cohorts that included people across the whole spectrum from normal to severely reduced function, so it does not extrapolate in the same way and stays calibrated at the top of the range — exactly where early CKD is detected or excluded.

Where They Agree and Where They Diverge

The pattern is consistent: the two equations converge as kidney function falls and diverge as it approaches normal. That is why MDRD remained acceptable for advanced disease for years, and why the switch to CKD-EPI matters most for detecting and grading early kidney disease.

Common Mistakes to Avoid

The main pitfall is trusting a near-normal MDRD value. A patient told their MDRD eGFR is “75” may actually have GFR closer to 90, and acting on the lower figure can label healthy kidneys as mildly diseased. Many laboratories sidestep this by reporting MDRD only as “greater than 60” rather than a precise high number. A second mistake is using either eGFR for drug dosing — both are staging tools, and dosing belongs to Cockcroft–Gault creatinine clearance. A third is assuming MDRD and CKD-EPI should match exactly; small differences at moderate GFR are normal and do not indicate a lab error.

A Second Worked Example

Take a 40-year-old woman with a serum creatinine of 0.8 mg/dL. MDRD returns roughly 80 mL/min/1.73m², which would suggest mildly reduced function (G2). CKD-EPI 2021 returns about 92 mL/min/1.73m² — normal function (G1). Same patient, same creatinine, but the staging conclusion flips, and the CKD-EPI value is the accurate one. This is precisely the near-normal scenario where MDRD should not be used to make a call.

The Shift From MDRD to CKD-EPI

The change was deliberate and evidence-driven. After MDRD became the default eGFR equation in the 2000s, large validation studies showed it consistently underestimated GFR at the near-normal end and could therefore misclassify healthy people as having early kidney disease. The CKD-EPI collaboration published its creatinine equation in 2009 to correct that bias, and clinical guidelines progressively endorsed it for reporting. The 2021 revision then removed the race coefficient that both earlier equations had carried. The result is that CKD-EPI 2021 is now the recommended equation for adult eGFR reporting, while MDRD persists mainly in legacy records and older laboratory systems.

Why Both Are Reported Race-Free Here

Both the original MDRD and the 2009 CKD-EPI equations included a separate multiplier for Black patients. That coefficient has since been judged to lack a biological basis and to risk underestimating disease severity, which could delay specialist referral or transplant evaluation. The 2021 CKD-EPI equation was re-fit without race, and this site applies MDRD without its race factor as well, so every adult eGFR on the site is computed race-free. This keeps the two equations comparable on the one axis — race handling — where they would otherwise differ from their original forms. See the race-free 2021 equation for the detail.

Reading an MDRD Result on an Old Report

Because MDRD still appears in records, knowing how to read it matters. If an older report shows an MDRD eGFR below about 60, it can usually be taken at face value and staged in the normal way. If it shows a value above 60, or simply “>60,” treat it as confirmation that function is at least moderate rather than as a precise figure, and re-estimate with CKD-EPI 2021 if a precise near-normal value is needed. Pairing the historical MDRD value with a current CKD-EPI value also gives a sense of trend, provided you remember the two will diverge most at the top of the range.

Which to Use When: The Verdict

Prefer CKD-EPI 2021 for all new staging. MDRD remains reasonable below 60 mL/min/1.73m² and is still widely reported, so you should recognise it, but it underestimates higher GFR and is no longer recommended for new use. Neither equation is for dosing — compare the separate dosing question in CrCl vs eGFR, and for the named dosing-vs-staging pairing see Cockcroft–Gault vs CKD-EPI.